Is there anything really novel on the antidepressant horizon?

Current Psychiatry Reports

Volumn 14, Issue 6, 2012, Pages 643-649

  Murrough, James W ^a   Charney, Dennis S ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressant; Drug discovery; Glutamate; Ketamine; Major depressive disorder; Mood disorders; N methyl d aspartate receptor; Psychiatry; Psychopharmacology; Treatment resistant depression

Indexed keywords

AMFEBUTAMONE; AMITIFADINE; ANTIDEPRESSANT AGENT; AZD 6765; BCI 224; BCI 632; BMS 820836; BREXPIPRAZOLE; CITALOPRAM; CX 157; DSP 1053; EDIVOXETINE; ESCITALOPRAM; GLUTAMIC ACID; GLYX 13; KETAMINE; MIFEPRISTONE; MILNACIPRAN; MIRTAZAPINE; NEUROTRANSMITTER; PLACEBO; RG 7090; SEP 228432; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TEDATIOXETINE; TGBA 01AD; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; VORTIOXETINE;

ANTIDEPRESSANT ACTIVITY; BIPOLAR DEPRESSION; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; MAJOR DEPRESSION; MONOAMINERGIC SYSTEM; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; SINGLE DRUG DOSE;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DRUG DISCOVERY; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; KETAMINE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84870824224     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-012-0321-8     Document Type: Review

References (48)

1. World Health Organization. The global burden of disease: 2004 update. 2008.
2. Collins PY, Patel V, Joestl SS, et al. Grand challenges in global mental health. Nature. 2011;475:27-30.
3. Berton O, Nestler EJ. New approaches to antidepressant drug discovery: Beyond monoamines. Nat Rev Neurosci. 2006;7:137-51. (Pubitemid 43151600)
4. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature. 2008;455:894-902.
5. Manji HK, Quiroz JA, Sporn J, et al. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry. 2003;53:707-42. (Pubitemid 39658487)
6. Mathew SJ, Manji HK, Charney DS. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008;33:2080-92. (Pubitemid 351992096)
7. Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358:252-60.
8. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: A patient-level meta-analysis. JAMA. 2010;303:47-53.
9. Undurraga J, Baldessarini RJ. Randomized, placebo-controlled trials of antidepressants for acute major depression: Thirty-year metaanalytic review. Neuropsychopharmacology. 2012;37:851-64.
10. Levkovitz Y, Tedeschini E, Papakostas GI. Efficacy of antidepressants for dysthymia: A meta-analysis of placebo-controlled randomized trials. J Clin Psychiatry. 2011;72:509-14.
11. Gartlehner G, Hansen RA, Morgan LC, et al. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: An updated meta-analysis. Ann Intern Med. 2011;155:772-85.
12. Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian network for mood and anxiety treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults III. Pharmacotherapy. J Affect Disord. 2009;117:S26-43.
13. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry. 2006;163:28-40. (Pubitemid 43050100)
14. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am J Psychiatry. 2006;163:1905-17. (Pubitemid 44807782)
15. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354:1231-42.
16. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354:1243-52.
17. Rush AJ, Trivedi MH, Stewart JW, et al. Combining medications to enhance depression outcomes (CO-MED): Acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry. 2011;168:689-701.
18. Pharmaceutical Research and Manufacturers of America (PhRMA). Medicines in development for mental illness report 2012.
19. Sanacora G, Zarate CA, Krystal JH, et al. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov. 2008;7:426-37. (Pubitemid 351619114)
20. Heninger GR, Delgado PL, Charney DS. The revised monoamine theory of depression: A modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry. 1996;29:2-11. (Pubitemid 26071332)
21. Ruhe HG, Mason NS, Schene AH. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: A meta-analysis of monoamine depletion studies. Mol Psychiatry. 2007;12:331-59. (Pubitemid 46496835)
22. Paul IA, Skolnick P. Glutamate and depression: Clinical and preclinical studies. Ann N Y Acad Sci. 2003;1003:250-72. (Pubitemid 38083061)
23. Skolnick P, Popik P, Trullas R. Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci. 2009;30:563-9.
24. Holtmaat A, Svoboda K. Experience-dependent structural synaptic plasticity in themammalian brain. Nat Rev Neurosci. 2009;10:647-58.
25. Pittenger C, Duman RS. Stress, depression, and neuroplasticity: A convergence of mechanisms. Neuropsychopharmacology. 2008;33:88-109. (Pubitemid 350191319)
26. Duman RS, Voleti B. Signaling pathways underlying the pathophysiology and treatment of depression: Novel mechanisms for rapid-acting agents. Trends Neurosci. 2012;35:47-56.
27. Arnone D, McIntosh AM, Ebmeier KP, et al. Magnetic resonance imaging studies in unipolar depression: Systematic review and meta-regression analyses. Eur Neuropsychopharmacol. 2012;22:1-16.
28. Mathew SJ, Shah A, Lapidus K, et al. Ketamine for treatmentresistant unipolar depression: Current evidence. CNS Drugs. 2012;26:189-204.
29. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351-4. (Pubitemid 30109248)
30. Zarate Jr CA, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856-64. (Pubitemid 44188478)
31. Aan Het Rot M, Zarate CA Jr, Charney DS, et al. Ketamine for depression: Where do we go from here? Biol Psychiatry. 2012, in press.
32. Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized addon trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010;67:793-802.
33. Zarate Jr CA, Brutsche NE, Ibrahim L, et al. Replication of ketamine's antidepressant efficacy in bipolar depression: A randomized controlled add-on trial. Biol Psychiatry. 2012;71:939-46.
34. Murrough JW, Perez AM, Pillemer S, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2012, in press.
35. Price RB, Nock MK, Charney DS, et al. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry. 2009;66:522-6.
36. DiazGranados N, Ibrahim LA, Brutsche NE, et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-Daspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry. 2010;71:1605-11.
37. Larkin GL, Beautrais AL. A preliminary naturalistic study of lowdose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol. 2011;14:1127-31.
38. Mathew SJ, Murrough JW, Aan het Rot M, et al. Riluzole for relapse prevention following intravenous ketamine in treatmentresistant depression: A pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol. 2010;13:71-82.
39. Ibrahim L, Diazgranados N, Franco-Chaves J, et al. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: Results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology. 2012;37:1526-33.
40. Aan het Rot M, Collins KA, Murrough JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatmentresistant depression. Biol Psychiatry. 2010;67:139-45.
41. Murrough JW, Perez AM, Mathew SJ, et al. A case of sustained remission following an acute course of ketamine in treatmentresistant depression. J Clin Psychiatry. 2011;72:414-5.
42. Li N, Lee B, Liu RJ, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329:959-64.
43. Li N, Liu RJ, Dwyer JM, et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry. 2011;69:754-61.
44. Autry AE, Adachi M, Nosyreva E, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 2011;475:91-5.
45. Beurel E, Song L, Jope RS. Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice. Mol Psychiatry. 2011;16:1068-70.
46. Maeng S, Zarate Jr CA, Du J, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: Role of alpha-amino-3-hydroxy-5- methylisoxazole-4-propionic acid receptors. Biol Psychiatry. 2008;63:349-52. (Pubitemid 351146651)
47. Cornwell BR, Salvadore G, Furey M, et al. Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatmentresistant major depression. Biol Psychiatry. 2012, in press.
48. Valentine GW, Mason GF, Gomez R, et al. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res. 2011;191:122-7.